Vertex Pharmaceuticals Inc (VRTX)
Working capital turnover
Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 | Mar 31, 2021 | Dec 31, 2020 | Sep 30, 2020 | Jun 30, 2020 | Mar 31, 2020 | ||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Revenue (ttm) | US$ in thousands | 10,984,000 | 10,582,900 | 10,283,600 | 10,120,000 | 9,803,200 | 9,596,700 | 9,444,700 | 9,144,300 | 8,863,500 | 8,628,770 | 8,277,080 | 7,873,370 | 7,499,400 | 7,066,960 | 6,622,470 | 6,355,190 | 6,147,530 | 5,935,020 | 5,347,582 | 4,763,428 |
Total current assets | US$ in thousands | 9,596,400 | 9,804,100 | 8,941,600 | 13,288,700 | 14,144,200 | 14,695,800 | 13,872,900 | 12,965,700 | 13,234,800 | 12,271,000 | 11,503,500 | 10,361,300 | 9,560,600 | 8,852,540 | 8,457,510 | 8,539,310 | 8,133,400 | 7,458,460 | 6,694,320 | 5,446,400 |
Total current liabilities | US$ in thousands | 3,564,600 | 3,973,100 | 3,547,200 | 3,795,900 | 3,547,400 | 3,599,400 | 3,352,100 | 3,026,200 | 2,742,100 | 2,609,300 | 2,556,200 | 2,180,200 | 2,142,000 | 1,914,260 | 1,836,450 | 1,944,050 | 1,877,500 | 2,004,030 | 1,798,640 | 1,538,750 |
Working capital turnover | 1.82 | 1.81 | 1.91 | 1.07 | 0.93 | 0.86 | 0.90 | 0.92 | 0.84 | 0.89 | 0.93 | 0.96 | 1.01 | 1.02 | 1.00 | 0.96 | 0.98 | 1.09 | 1.09 | 1.22 |
December 31, 2024 calculation
Working capital turnover = Revenue (ttm) ÷ (Total current assets – Total current liabilities)
= $10,984,000K ÷ ($9,596,400K – $3,564,600K)
= 1.82
Vertex Pharmaceuticals Inc's working capital turnover has exhibited fluctuations over the period analyzed. The ratio started at 1.22 on March 31, 2020, reflecting that the company generated $1.22 in revenue for every dollar of working capital invested. However, the ratio decreased to 0.84 by December 31, 2022 before gradually recovering. Notably, an increase in working capital turnover indicates an improvement in efficiency in utilizing working capital to generate revenue.
The ratio saw a significant improvement to 1.91 on June 30, 2024, suggesting that Vertex Pharmaceuticals Inc was able to generate $1.91 in revenue for each dollar of working capital invested, which could be due to better management of its working capital components such as current assets and current liabilities. Overall, analyzing the working capital turnover can provide insights into how effectively the company is utilizing its working capital to support its operations and generate revenue.
Peer comparison
Dec 31, 2024
See also:
Vertex Pharmaceuticals Inc Working Capital Turnover (Quarterly Data)